[Test of efficacy of an oxalate-binding anion exchanger Colestid in healthy subjects for use in idiopathic calcium-oxalate urolithiasis].
Sodium oxalate (402 mg) was administered in a single dose to 10 healthy volunteers receiving a controlled diet. Half the group received 3 times 10 g Colestid and the other half 4 times 2 g Andursil. On the 5th day the oxalate load was repeated. Urine was collected within 32 hours following oxalate application in 8 fractions. In each fraction the levels of oxalate, calcium, phosphate and uric acid were determined. The amount of oxalate, phosphate and uric acid measured in the group receiving Colestid was lower in all fractions. Peak excretions of oxalate found in unmedicated volunteers were suppressed following oxalate load. In the group receiving Andursil, only the excretion of phosphate was decreased. The results presented suggest that Colestid may be promising in the prevention of calcium-oxalate-urolithiasis.
D000837:Anion Exchange Resins / Q000494:pharmacology*; D002129:Calcium Oxalate / Q000652:urine; D003084:Colestipol / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D007475:Ion Exchange Resins / Q000494:pharmacology*; D011073:Polyamines / Q000494:pharmacology*; D014545:Urinary Calculi / Q000188:drug therapy* / Q000517:prevention & control / Q000652:urine
D000837:Anion Exchange Resins; D007475:Ion Exchange Resins; D011073:Polyamines; D002129:Calcium Oxalate; D003084:Colestipol
Prüfung der Wirksamkeit eines oxalatbindenden Anionenaustauschers Colestid an gesunden Probanden zum Einsatz bei der idiopathischen Calcium-Oxalat-Urolithiasis.